The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
AGY must pleased with the outcome of the study, Dr. Shamji will summarise the findings of the Group’s ex vivo VLP Peanut 001 biomarker study which, as announced on 3 August 2021, showed the hypoallergenic potential of the vaccine candidate, due to enter the clinic in Q1 2022. maybe further news in the results 23rd Sept. You would think this would then shift upwards quickly catching people out
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has today announced that it will host a webinar entitled ‘VLP Peanut; a next generation peanut allergy immunotherapy’, on Friday 17 September 2021 at 14.00 BST, 09.00 EDT.
The webinar will include an introduction from Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, and a feature presentation by key opinion leader (KOL), Dr. Mo Shamji, Reader in Immunology & Allergy at Imperial College London.
Dr. Shamji will summarise the findings of the Group’s ex vivo VLP Peanut 001 biomarker study which, as announced on 3 August 2021, showed the hypoallergenic potential of the vaccine candidate, due to enter the clinic in Q1 2022.
Dr. Matt Heath, Principal Scientist at Allergy Therapeutics, will also provide an overview presentation on the Group’s novel virus-like particle (VLP) technology.
The presentation will be followed by a live Q&A session and details can be accessed on the Group’s website at https://www.allergytherapeutics.com/investors/results-reports-and-presentations/. A replay of both will be made available on the website shortly after the event.
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Shouldn't worry about it. My buy today is showing as a sell. Try a dummy buy or sell and see what prices you are quoted. That will show the truth. Never trust the buy/sell figures shown here or anywhere else. As TeesExile says, it's only a computer guess.
FY results 23rd Sept not today.
Full year results released next Friday 3rd Sept, should be all good news
I don't know, but perhaps they are not all sells - often the automatic assignment of buys and sells is misled because the true spread is not symmetrically placed within the published spread. i.e. if published spread is 32 - 33 but one is quoted 32.49 to buy it will be automatically identified as a sell. If they were all sells one would expect MMs to adjust the price down, which hasn't happened.
Can be many reasons to sell which are unrelated to company news. i.e. need cash, or need to wrap assets within tax-sheltered account, or see better use for investment elsewhere.
I am not worried!
2 large sells yesterday, 1.1m each and todays 200k and 125k sell offs, why, no bad news.
What is driving this ?
Mis-type, try these
https://www.***************************/allergy-therapeutics-begin-grass-mata-mpl-exploratory-study/412867783
https://www.standard.co.uk/business/pharmaceuticals/peanut-allergy-vaccine-allergy-therapeutics-fda-b948966.html
This is why we need to stay with this company, generate real revenues increasing year on year and 2 huge opportunities ongoing that could be game changing Grass MATA MPL study has been running for nearly 1 year, soon be results.https://www.***************************/allergy-therapeutics-begin-grass-mata-mpl-exploratory-study/412867783Ground-breaking and disruptive vaccine candidate, VLP Peanut.Investigational New Drug submission at the end of this year and expected initiation of our Phase I trial in 2022.https://www.standard.co.uk/business/pharmaceuticals/peanut-allergy-vaccine-allergy-therapeutics-fda-b948966.html
Good move, Ignore the sells, this is moving slowly towards forecast of 57p based on Grass mata and Ex viva study
half-way there - confess I had another top-up this afternoon
Interesting article in the times 4 page article on new treatment for peanut allergy suffers, doesn’t look as good as the new vaccine treatment that AGY are bringing to market. We need same publicity for AGY to get things moving.
https://www.thetimes.co.uk/article/peanut-allergy-treatment-new-drug-palforzia-djv3bmrdr
Good question about market cap! Something I've tried working out but quickly gave up. A peanut and / or one of the other new drugs in the pipeline would have a transformative effect on the business. It would provide significant cash flow for future projects, deliver bumper long term profits but also put AGY in the shop window (if it's not already). So, I could easily see market cap rising by x3 - but that maybe greed kicking in! I added some more stock earlier in the week. Although I'm confident in low term growth it's always a little worrying buying at an sp a lot higher than it has traditionally been trading at over the past few years!
Next target 35p onwards and upwards
As I said a week ago 30p very soon, encouraging all buys, nothing negative to worry about., who in their right mind would sell knowing what’s coming. Be patient, the share price will move quickly to catch people out.
It's a good board this, I've enjoyed reading some of the contributions. Having dipped my toes in earlier in the year at 24p, I'm interested to know what peoples thoughts are on a realistic market cap for AGY?
I keep reading about the market potential for peanut allergy, which of course AGY are some way off having an approved product, but it does appear they have a promising potential solution. Appreciate the thoughts of others
Slow and steady - just the way we like it!
AGY is a class operation.
this is the sort of SP movement I like: nice steady rise on the back of the very good ex vivo peanut trial results recently made public. I more than doubled my holding about a month ago, and doubled it again this week. As Padd1 noted, this seems a very well-run business. Good calm interviews and presentations this week. What's not to like?
Great news, hope Abbott Laboratories start to increase holding now progress has been made in this development
Trials.
All in good time. Positive news.
yes but years to go....and many trails.
Update on Peanut VLP 001 - fantastic progress made.
Exciting times ahead for AGY!!
Soon be 30p, MM’s playing games at the moment